76.82

0.08% 0.06

After Hours: 77.32 0.50 +0.65%

Ionis Pharmaceuticals Inc (IONS)

Overview News Price History Option Chain Financials Discussions Forecast

Ionis Pharmaceuticals Inc stock is traded at $76.82, with a volume of 1.29M. It is up +0.08% in the last 24 hours and up +7.91% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Previous Close:

$76.76

Open:

$77.1

24h Volume:

1.29M

Relative Volume:

0.58

Market Cap:

$12.69B

Revenue:

$943.38M

Net Income/Loss:

$-380.99M

P/E Ratio:

-31.14

EPS:

-2.4667

Net Cash Flow:

$-325.67M

1W Performance:

+2.45%

1M Performance:

+7.91%

6M Performance:

+6.12%

1Y Performance:

+170.68%

1-Day Range:

$75.77

$77.18

1-Week Range:

$74.53

$77.38

52-Week Range:

$27.57

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name

Ionis Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(760) 931-9200

Address

2855 GAZELLE COURT, CARLSBAD, CA

Employee

1,402

Twitter

@ionispharma

Next Earnings Date

2024-11-06

Latest SEC Filings

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IONS Ionis Pharmaceuticals Inc	76.82	12.68B	943.38M	-380.99M	-325.67M	-2.4667
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Resumed	Raymond James	Outperform
Jan-28-26	Resumed	Barclays	Overweight
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-26-25	Upgrade	Goldman	Sell → Neutral
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight
Apr-07-25	Initiated	H.C. Wainwright	Buy
Mar-31-25	Initiated	Redburn Atlantic	Neutral
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-16-24	Resumed	Jefferies	Buy
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral
Sep-29-23	Initiated	Raymond James	Strong Buy
Jul-31-23	Upgrade	Citigroup	Neutral → Buy
Jun-07-23	Resumed	Piper Sandler	Overweight
May-04-23	Upgrade	Citigroup	Sell → Neutral
Mar-21-23	Initiated	Bernstein	Underperform
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-09-22	Resumed	Morgan Stanley	Overweight
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-01-22	Initiated	Citigroup	Sell
Mar-01-22	Initiated	Guggenheim	Buy
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight
Dec-16-20	Initiated	UBS	Sell
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral
Sep-02-20	Initiated	The Benchmark Company	Hold
Jun-01-20	Resumed	Oppenheimer	Outperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-05-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
Nov-07-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-10-19	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-08-18	Reiterated	Stifel	Hold
Aug-07-18	Reiterated	Stifel	Hold
May-08-18	Downgrade	Evercore ISI	Outperform → In-line
Oct-06-17	Resumed	Goldman	Sell
Aug-17-17	Initiated	Evercore ISI	Outperform
Aug-09-17	Reiterated	Stifel	Hold
Mar-10-17	Downgrade	Goldman	Neutral → Sell
Dec-28-16	Reiterated	BMO Capital Markets	Outperform
Dec-27-16	Reiterated	Leerink Partners	Mkt Perform

View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

10:40 AM

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com

10:40 AM

07:06 AM

Ionis to hold first quarter 2026 financial results webcast - The Joplin Globe

07:06 AM

04:10 AM

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

04:10 AM

04:07 AM

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

04:07 AM

04:06 AM

Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript - GuruFocus

04:06 AM

Apr 13, 2026

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance

Apr 13, 2026

Apr 10, 2026

Winners Losers: Is Ionis Pharmaceuticals Inc a top pick in the sector2026 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Ionis Pharmaceuticals (IONS) Receives Updated Analyst Rating fro - GuruFocus

Apr 09, 2026

BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating - Moomoo

Apr 09, 2026

IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

Apr 09, 2026

Apr 08, 2026

Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com

Apr 08, 2026

Apr 07, 2026

Will Ionis Pharmaceuticals Inc benefit from sector rotation2026 Price Targets & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Apr 07, 2026

Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors - TipRanks

Apr 07, 2026

Apr 06, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire Inc.

Apr 06, 2026

Apr 05, 2026

Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN

Apr 04, 2026

IONS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

IONS PE Ratio & Valuation, Is IONS Overvalued - Intellectia AI

Apr 04, 2026

IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN

Apr 04, 2026